Compass Pathways (CMPS) Expected to Announce Earnings on Thursday

Compass Pathways (NASDAQ:CMPS) will likely be issuing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.39) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 5, 2026 at 2:00 AM ET.

Compass Pathways Price Performance

CMPS stock opened at $7.99 on Wednesday. Compass Pathways has a 52 week low of $2.25 and a 52 week high of $8.90. The firm has a market capitalization of $767.20 million, a P/E ratio of -2.94 and a beta of 1.92. The company has a fifty day simple moving average of $6.91 and a two-hundred day simple moving average of $6.02. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.55.

Hedge Funds Weigh In On Compass Pathways

A number of large investors have recently made changes to their positions in CMPS. Royal Bank of Canada lifted its holdings in shares of Compass Pathways by 49.8% during the 1st quarter. Royal Bank of Canada now owns 89,446 shares of the company’s stock valued at $256,000 after purchasing an additional 29,733 shares during the last quarter. Acadian Asset Management LLC increased its position in Compass Pathways by 42.0% during the 1st quarter. Acadian Asset Management LLC now owns 240,591 shares of the company’s stock valued at $686,000 after buying an additional 71,112 shares in the last quarter. Nantahala Capital Management LLC raised its stake in Compass Pathways by 47.7% in the second quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock valued at $11,704,000 after buying an additional 1,350,698 shares during the last quarter. Balyasny Asset Management L.P. raised its stake in Compass Pathways by 38.0% in the second quarter. Balyasny Asset Management L.P. now owns 854,840 shares of the company’s stock valued at $2,394,000 after buying an additional 235,345 shares during the last quarter. Finally, Northeast Financial Consultants Inc acquired a new stake in Compass Pathways in the second quarter worth about $59,000. 46.19% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CMPS has been the topic of a number of analyst reports. Canaccord Genuity Group upped their target price on Compass Pathways from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Lifesci Capital upgraded Compass Pathways to a “strong-buy” rating in a report on Thursday, February 12th. Compass Point set a $15.00 target price on shares of Compass Pathways in a research report on Thursday, February 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Pathways in a report on Wednesday, January 21st. Finally, Morgan Stanley upped their price target on shares of Compass Pathways from $11.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $17.56.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.